Con: Factor Concentrate Usage in Cardiac Surgery—A Paucity of Data Limits Their Universal Adoption

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 2, 2018, Pages 1068-1071

  Raleigh, Lindsay ^a   Cole, Sheela Pai ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

coagulopathy; factor concentrates; fresh frozen plasma; prothrombin complex concentrate; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 9 COMPLEX; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN;

BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; NOTE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; HEART SURGERY;

BLOOD COAGULATION FACTORS; CARDIAC SURGICAL PROCEDURES; RECOMBINANT PROTEINS;

EID: 85029620127     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.05.005     Document Type: Note

References (33)

1. Christensen, M.C., Krapf, S., Kempel, A., et al. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 138 (2009), 687–693.
2. Murphy, G.J., Reeves, B.C., Rogers, C.A., et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 116 (2007), 2544–2552.
3. Reeves, B.C., Murphy, G.J., Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery. Curr Opin Cardiol 23 (2008), 607–612.
4. Scott, B.H., Seifert, F.C., Grimson, R., Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth 11 (2008), 15–19.
5. Gorlinger, K., Dirkmann, D., Hanke, A.A., et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study. Anesthesiology 115 (2011), 1179–1191.
6. Deppe, A.C., Weber, C., Zimmermann, J., et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: A meta-analysis of 8332 patients. J Surg Res 203 (2016), 424–433.
7. Vasques, F., Spiezia, L., Manfrini, A., et al. Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: A retrospective observational study. J Anesth 31 (2017), 286–290.
8. Rana, R., Fernandez-Perez, E.R., Khan, S.A., et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: A retrospective study. Transfusion 46 (2006), 1478–1483.
9. Dijkhuizen, A., De Bruin, R., Arbous, S., Incidence, risk factors and outcome of TRALI after cardiac surgery. Crit Care, 17, 2013, P373.
10. Gill, R., Herbertson, M., Vuylsteke, A., et al. Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120 (2009), 21–27.
11. Diprose, P., Herbertson, M.J., O׳Shaughnessy, D., et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 95 (2005), 596–602.
12. Yank, V., Tuohy, C.V., Logan, A.C., et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Int Med 154 (2011), 529–540.
13. Levi, M., Levy, J.H., Andersen, H.F., et al. Safety of recombinant activated factor VII in randomized clinical trials. New Engl J Med 363 (2010), 1791–1800.
14. O׳Connell, K.A., Wood, J.J., Wise, R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006), 293–298.
15. Steiner, T., Poli, S., Griebe, M., et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): A randomised trial. Lancet Neurol 15 (2016), 566–573.
16. Fariborz Farsad, B., Golpira, R., Najafi, H., et al. Comparison between prothrombin complex concentrate (PCC) and fresh frozen plasma (FFP) for the urgent reversal of warfarin in patients with mechanical heart valves in a tertiary care cardiac center. Iran J Pharm Res 14 (2015), 877–885.
17. Ortmann, E., Besser, M.W., Sharples, L.D., et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 121 (2015), 26–33.
18. Demeyere, R., Gillardin, S., Arnout, J., et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: A randomized study. Vox Sang 99 (2010), 251–260.
19. Cappabianca, G., Mariscalco, G., Biancari, F., et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care, 20, 2016, 5.
20. Arnekian, V., Camous, J., Fattal, S., et al. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Inter Cardiovasc Thorac Surg 15 (2012), 382–389.
21. Sorensen, B., Spahn, D.R., Innerhofer, P., et al. Clinical review: Prothrombin complex concentrates—Evaluation of safety and thrombogenicity. Crit Care, 15, 2011, 409.
22. Leissinger, C.A., Blatt, P.M., Hoots, W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Amer J Hematol 83 (2008), 137–143.
23. Majeed, A., Eelde, A., Agren, A., et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 129 (2012), 146–151.
24. Grottke, O., Levy, J.H., Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology 122 (2015), 923–931.
25. Karlsson, M., Ternstrom, L., Hyllner, M., et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion 48 (2008), 2152–2158.
26. Rahe-Meyer, N., Pichlmaier, M., Haverich, A., et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: A pilot study. Br J Anaesth 102 (2009), 785–792.
27. Rahe-Meyer, N., Solomon, C., Hanke, A., et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 118 (2013), 40–50.
28. Ranucci, M., Baryshnikova, E., Crapelli, G.B., et al. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc, 4, 2015, e002066.
29. Sadeghi, M., Atefyekta, R., Azimaraghi, O., et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery. Braz J Anesthesiol 64 (2014), 253–257.
30. Galas, F.R., de Almeida, J.P., Fukushima, J.T., et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. J Thorac Cardiovasc Surg 148 (2014), 1647–1655.
31. Tanaka, K.A., Egan, K., Szlam, F., et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: Preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 54 (2014), 109–118.
32. Jeppsson, A., Walden, K., Roman-Emanuel, C., et al. Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. Br J Anaesth 116 (2016), 208–214.
33. Rahe-Meyer, N., Levy, J.H., Mazer, C.D., et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): A double-blind phase III study of haemostatic therapy. Br J Anaesth 117 (2016), 41–51.